Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience

다국어 초록 (Multilingual Abstract)

Purpose: The International Organization for Standardization-5fluorouracil (FU) 10 trial found that bolus 5-FU and l-leucovorin was not inferior to S-1 in the treatment of gastric cancer (GC). Continuous 5-FU and the rapid injection of 5-FU have different anti-cancer effects.

Thus, bolus 5-FU and l-leucovorin treatment might be useful for oral FU-resistant GC.

Materials and Methods: We retrospectively analyzed the medical records of all patients with S-1 or capecitabine-resistant, unresectable, or recurrent GC treated with bolus 5-FU and l-leucovorin between January 2010 and December 2015 at Hokkaido University Hospital.

The bolus 5-FU and l-leucovorin regimen consisted of intravenous l-leucovorin (250 mg/m2/2 h) and bolus 5-FU (600 mg/m2) administered once weekly followed by a 2-week rest period; each cycle was repeated every 8 weeks.

Results: A total of 14 patients were identified. The disease control rate was 35.7%. The median progression-free survival was 1.6 months (95% confidence interval [CI], 1.3~2.0 months), and the median overall survival was 6.3 months (95% CI, 4.7~7.9 months). No patient died from treatment-related causes. The most common severe adverse event associated with bolus 5-FU and lleucovorin was neutropenia, which occurred in 21.4% of patients.

Conclusions: Bolus 5-FU and l-leucovorin treatment might be useful for oral FU-resistant GC. We are planning a multi-center prospective phase II trial to evaluate the efficacy and safety of bolus 5-FU and l-leucovorin treatment for pre-treated unresectable or recurrent GC to confirm the results of this limited, retrospective study.

참고문헌 (Reference)

1 Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial" 376 : 687-697, 2010

2 Shitara K, "Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW : a randomized clinical trial in second-line treatment of gastric cancer" 19 : 927-938, 2016

3 Kang JH, "Salvage chemotherapy for pretreated gastric cancer : a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone" 30 : 1513-1518, 2012

4 Koizumi W, "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial) : a phase III trial" 9 : 215-221, 2008

5 Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind, randomised phase 3 trial" 15 : 1224-1235, 2014

6 Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial" 383 : 31-39, 2014

7 Yamada Y, "Phase III study comparing oxaliplatin plus S-1with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer" 26 : 141-148, 2015

8 Parker WB, "Metabolism and mechanism of action of 5-fluorouracil" 48 : 381-395, 1990

9 Ohtsu A, "Everolimus for previously treated advanced gastric cancer:results of the randomized, double-blind, phase III GRANITE-1study" 31 : 3935-3943, 2013

10 Sawaki A, "Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer : a subgroup analysis of the Trastuzumab for Gastric Cancer(ToGA)study" 15 : 313-322, 2012

11 Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer" 358 : 36-46, 2008

12 Longley DB, "5-fluorouracil : mechanisms of action and clinical strategies" 3 : 330-338, 2003

13 Sawaki A, "5-FU/l-LV(RPMI)versus S-1 as first-line therapy in patients with advanced gastric cancer : a randomized phase III non-inferiority trial(ISO-5FU10 Study Group trial)" 7 : 364-, 2009